Skip to main navigation Skip to search Skip to main content

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

EORTC Melanoma Group

365 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Neuroscience

Keyphrases

Immunology and Microbiology